CTIS2023-507846-96-00进行中（未招募）1 期
I8F-MC-GPGN: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) - I8F-MC-GPG
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 13,299
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have a diagnosis of type 2 diabetes, Have confirmed atherosclerotic cardiovascular disease, HbA1c =7.0% to =10.5%, Body mass index (BMI) =25 kilograms per meter squared (kg/m²)
排除标准
- •Have had a major cardiovascular event within the last 60 days, Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2), Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement, Have type 1 diabetes mellitus, Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months, Are currently planning treatment for diabetic retinopathy and/or macular edema, Currently planning a coronary, carotid, or peripheral artery revascularization, Have a history of pancreatitis, Have a history of ketoacidosis or hyperosmolar state/coma, Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery, Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
研究者
相似试验
进行中（未招募）
3 期
Patients with major Adverse Events With Type 2 DiabetesCTRI/2020/04/024938Eli Lilly and Company India Pvt Ltd
进行中（未招募）
1 期
The Effect of the drug Tirzepatide compared with the drug Dulaglutide on the Cardiovascular Risk in Patients with Type 2 DiabetesType 2 diabetes mellitusMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2019-002735-28-PLEli Lilly and Company12,500
进行中（未招募）
1 期
The Effect of the drug Tirzepatide compared with the drug Dulaglutide onthe Cardiovascular Risk in Patients with Type 2 DiabetesType 2 diabetes mellitusEUCTR2019-002735-28-ROEli Lilly and Company12,500
进行中（未招募）
1 期
The Effect of the drug Tirzepatide compared with the drug Dulaglutide on the Cardiovascular Risk in Patients with Type 2 DiabetesType 2 diabetes mellitusMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2019-002735-28-DEEli Lilly and Company12,500
进行中（未招募）
1 期
The Effect of the drug Tirzepatide compared with the drug Dulaglutide on the Cardiovascular Risk in Patients with Type 2 DiabetesType 2 diabetes mellitusMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2019-002735-28-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER12,500